Search research articles
Contact Us
Filters
Showing results (71-80 of 79) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 79 results.
Experimental Hematology
|
June 14, 2008
montalcino, A zebrafish model for variegate porphyria
Kimberly A Dooley, Paula G Fraenkel, Nathaniel B Langer, et al.
American Journal of Hematology
|
October 9, 2018
Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident
Larysa Poluben, Maneka Puligandla, Donna Neuberg, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 23, 2025
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report
Xiuning Le, Christina Baik, Byoung Chul Cho, et al.
Cancer Research Communications
|
September 3, 2025
IPH5201, an anti-CD39 monoclonal antibody, as monotherapy or in combination with durvalumab in advanced solid tumors
John Powderly, Martina Imbimbo, Antoine Italiano, et al.
Blood Advances
|
August 14, 2025
Vaccine-Educated T cells and a CD123 Bispecific T-Cell Engager for Treatment of Acute Myeloid Leukemia
Jessica Liegel, Dina Stroopinsky, Giulia Cheloni, et al.
Oncoimmunology
|
September 6, 2021
Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment
Hélène Bonnevaux, Stephane Guerif, Jana Albrecht, et al.
JTO Clinical and Research Reports
|
April 27, 2026
Durvalumab Plus Chemotherapy in Patients With <i>EGFR</i>-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD
Byoung Chul Cho, Makoto Nishio, Myung-Ju Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD
Sarah B Goldberg, Myung-Ju Ahn, Christina Baik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2025
Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
Jason J Zoeller, Ravinder Tammali, Roger B Dodd, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 79) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 79 results.
Experimental Hematology
|
June 14, 2008
montalcino, A zebrafish model for variegate porphyria
Kimberly A Dooley, Paula G Fraenkel, Nathaniel B Langer, et al.
American Journal of Hematology
|
October 9, 2018
Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident
Larysa Poluben, Maneka Puligandla, Donna Neuberg, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 23, 2025
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report
Xiuning Le, Christina Baik, Byoung Chul Cho, et al.
Cancer Research Communications
|
September 3, 2025
IPH5201, an anti-CD39 monoclonal antibody, as monotherapy or in combination with durvalumab in advanced solid tumors
John Powderly, Martina Imbimbo, Antoine Italiano, et al.
Blood Advances
|
August 14, 2025
Vaccine-Educated T cells and a CD123 Bispecific T-Cell Engager for Treatment of Acute Myeloid Leukemia
Jessica Liegel, Dina Stroopinsky, Giulia Cheloni, et al.
Oncoimmunology
|
September 6, 2021
Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment
Hélène Bonnevaux, Stephane Guerif, Jana Albrecht, et al.
JTO Clinical and Research Reports
|
April 27, 2026
Durvalumab Plus Chemotherapy in Patients With <i>EGFR</i>-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD
Byoung Chul Cho, Makoto Nishio, Myung-Ju Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD
Sarah B Goldberg, Myung-Ju Ahn, Christina Baik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2025
Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
Jason J Zoeller, Ravinder Tammali, Roger B Dodd, et al.
Page
of 8